Project
A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-dose Therapy
Ongoing - recruitment closed · 2019 until 2025
Schittenhelm Marcus, Berbic Hong Phuong, Quinter Janine
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment closed
Start Date
2019
End Date
2025
Financing
Industry
Labels
myeloma